Bioxel Pharma Inc.

Bioxel Pharma Inc.

November 18, 2005 09:44 ET

Bioxel Pharma Broadens its Taxane Product Line

SAINTE-FOY, QUEBEC--(CCNMatthews - Nov. 18, 2005) - Bioxel Pharma Inc. (TSX VENTURE:BIP), a leading manufacturer and supplier of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, today announced the filing of a new patent covering the manufacturing of paclitaxel and docetaxel APIs by semi-synthesis.

"This new intellectual property serves clear commercial objectives" said Pascal Delmas, President and CEO of Bioxel. "First, it will broaden our product line; an objective Bioxel established in its 2005 road map. Second, it will satisfy the demand of our pharmaceutical partners that are seeking semi-synthetic taxanes manufactured using highly efficient processes with guarantied freedom to operate". Mr Delmas added, "These patents not only strengthen Bioxel's market position for paclitaxel, they also allows us to develop our new docetaxel product, for which there is a significant market opportunity".

Bioxel filed a patent that protects complete synthetic routes to these two commercial taxane ingredients. It strengthens and extends the patent previously filed by the Corporation in March of 2005 on synthetic taxane intermediates. "This patent protects novel side chain precursors that take advantage of chiral auxiliaries in the synthesis of commercial taxanes" commented Dr. Gaetan Caron, Vice President, Research and Development of Bioxel Pharma. "It covers composition of matter on the auxiliaries, the corresponding taxane intermediates and processing methods used to manufacture paclitaxel and docetaxel starting from the naturally occurring intermediates 10-DAB or 9-DHB".

Docetaxel is the active pharmaceutical ingredient manufactured by Sanofi-Aventis and marketed under the trade name Taxotere®. Today, Taxotere® generates annual worldwide revenues of about US $2 billion. Generic drug product manufacturers are positioning themselves now to take advantage of patent expiration on docetaxel composition of matter which begins in 2007.

Bioxel now has a complete taxanes product line including natural and semi-synthetic paclitaxel, docetaxel, 9-DHB and 10-DAB. The Corporation is ideally positioned to grow sales in every segments of the taxane APIs market. Bioxel is discussing the supply of semi-synthetic taxanes with pharmaceutical customers for deliveries starting in 2006.


Bioxel Pharma Inc. is an emerging leader in biopharmaceuticals, focused on developing, manufacturing and marketing taxane pharmaceutical ingredients. Taxanes are used in drug products for the treatment of cancer and other diseases, including psoriasis, rheumatoid arthritis, Alzheimer's disease and cardiovascular disease. The Corporation sells cGMP paclitaxel and develops a portfolio of other generic taxane APIs and taxane-based proprietary products for improved cancer therapy.

This announcement includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. These include risks and uncertainties that could affect Bioxel's products under development such as regulatory factors, technological developments and competitive factors. Achievement of the objectives set forth in this release is subject to these risks and uncertainties. The Corporation's results, or the measures it adopts, could differ materially from those indicated or underlying these statements, or could have an impact on the realization of financial projections.

The TSX Venture Exchange has not reviewed the contents of this press release and accepts no responsibility for the adequacy or the accuracy thereof.

Contact Information

  • Bioxel Pharma Inc.
    Pascal Delmas, Pharm.D, MBA
    President and Chief Executive Officer
    (418) 654-9666